Novo Nordisk launched the FDA-approved oral Wegovy pill in January 2026, driving a 19% share rally as the first daily semaglutide expands its obesity franchise. The company warned intensifying GLP-1 competition and loss of exclusivity in key markets will pose near-term headwinds for international operations in 2026.